Executive Summary Information
|Mechanisms||Fluoxetine is a classic cationic amphiphilic compound that physically associates with phospholipids, causing intracellular sequestration and accumulation.|
|Comments||Fluoxetine was selected as a standard for hepatic phospholipidosis with minimal additional complicating activities in the liver.|
|Feedback Contact||Gold Compound Working Group (GCWG)|
|Target||Selective serotinin reuptake inhibitor (SSRI),NMDA receptors containing the GluN2B|
FDA and Label Information
The following link will display all of the currently approved FDA drug products on the market. The web page will contain a table listing all current products by their respective Tradenames and primary active ingredients. The list is navigable by simply clicking on the product of interest, which will in turn list all of the NDA's and ANDA's associated with that product. From here users can click on a specific NDA or ANDA and see documents that have been submitted for the product that the FDA has made available via their website. The types of documents include approval history, letters, reviews and labels.
FDA Approved Products
This next url will perform a search in the FDA's system for all labels for products that contain Fluoxetine as an active ingredient.
FDA Label Search
The following resource link will perform a PubMed query for the terms " Fluoxetine " and "liver toxicity".
The following resource link will perform a PubMed query for the terms " Fluoxetine " and "cardio toxicity".
The recommended source is Sigma Aldrich, product number 34012.
|Mol Weight||Fluoxetine hydrochloride 345.79|
|Brand||Fluka VETRANAL analytical standard|
|Comment||The product is a racemate of two enantiomers. The purity is not specified on the website and refers to the certificate of analysis of the batch available in October 2011 (szba306xv)|
|Storage||Store at room temperature|